| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3235305 | Apollo Medicine | 2012 | 7 Pages |
Abstract
The hallmark of ovarian cancer treatment, over decades, is accurate diagnosis, precise surgical staging, and optimal cytoreduction, followed by chemotherapy in the majority of cases. However, it is distressing to see the development of disease recurrence, resistance, and poor prognosis. Ovarian cancer cells express gene signatures, which pose significant challenges for cancer drug development. The aim of this review is to discuss the recent developments in terms of screening, surgical management, newer chemotherapeutic agents and molecular targeted therapies to improve the overall prognosis of ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
Usha Bohra,